Related Experiment Video

Updated: Jun 18, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Novel imatinib derivatives with altered specificity between Bcr-Abl and FMS, KIT, and PDGF receptors

Konstantinos Skobridis1, Maria Kinigopoulou, Vassiliki Theodorou

  • 1Department of Chemistry, Section of Organic Chemistry and Biochemistry, University of Ioannina, 45110 Ioannina, Greece. kskobrid@cc.uoi.gr

Chemmedchem
|December 2, 2009
PubMed

Insights

New imatinib derivatives show enhanced activity against platelet-derived growth factor (PDGF) receptors but reduced activity against Abl kinase. These compounds offer a platform for developing targeted therapies for PDGF receptor-driven cancers.

Area of Science:

  • Medicinal Chemistry
  • Oncology
  • Pharmacology

Background:

  • Imatinib is a crucial ATP-analogue inhibitor targeting Abl kinase and platelet-derived growth factor (PDGF) receptors.
  • Imatinib has transformed chronic myeloid leukemia treatment and is used for solid tumors with PDGF receptor mutations.
  • Understanding how drug design modifications impact biological activity is vital for rational drug development.

Purpose of the Study:

  • To synthesize and evaluate novel imatinib derivatives.
  • To investigate the impact of structural modifications on inhibitory activity against Abl and PDGF receptors.
  • To explore new therapeutic strategies targeting the PDGF receptor family.

Main Methods:

  • Synthesis of novel imatinib derivatives with modifications to the phenyl and N-methylpiperazine rings.
  • In vitro assays to assess the inhibitory activity of derivatives against Abl and PDGF receptors.
  • Comparative analysis of the biological activity of new derivatives against the parent imatinib molecule.

Main Results:

  • The new imatinib derivatives generally exhibited increased activity against PDGF receptors.
  • These derivatives showed decreased activity against Abl kinase compared to imatinib.
  • Structural modifications led to altered selectivity profiles.

Conclusions:

  • The developed imatinib derivatives serve as a foundation for further drug development targeting the PDGF receptor family.
  • These compounds provide valuable insights into engineering drugs with modified biological activity and selectivity.
  • The findings contribute to the rational design of kinase inhibitors for cancer therapy.

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...